Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivacaftor - Vertex Pharmaceuticals

Drug Profile

Ivacaftor - Vertex Pharmaceuticals

Alternative Names: IVA; Kalydeco; Potentiator VX-770; VRT 813077; VX-770

Latest Information Update: 13 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 26 Apr 2024 European Commission approves ivacaftor for Cystic fibrosis for infants down to 1 month of age with CFTR gene mutations
  • 23 Feb 2024 The CHMP of EMA adopts a positive opinion recommending expansion of usage of ivacaftor for treatment of Cystic fibrosis (In infants aged 1-4 months)
  • 02 Oct 2023 Vertex Pharmaceuticals completes a phase III trial for Cystic fibrosis (In neonates, In infants, In children) in USA, Australia, Canada, Germany, Ireland and United Kingdom (NCT03277196)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top